[Research on the Immunotherapy of T Cell Exhaustion in Multiple Myeloma --Review]

Multiple myeloma (MM) has strong heterogeneity and is still an incurable tumor. The new immunotherapy represented by bispecific antibody (BsAb) and chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown significant efficacy in MM treatment. However, these therapies directly utilize T cell activity, and the efficacy is affected by the functional state of T cells. T cell exhaustion (Tex), one of the important characteristics of MM, is closely related to the progression, drug resistance, recurrence, and poor prognosis of MM. Therefore, Tex is the key factor limiting the efficacy of BsAb and CAR-T technologies. This article reviews the latest research progress on the mutual influence between Tex and these therapies.